Scott Millman, MD PhD

Medical Oncologist and Leukemia Researcher at MSKCC. Tweets are my own.

[Kal Tsanov @ktsanov]

18 years ago, I came to the US to pursue my dream of becoming a scientist. Last week marked a major milestone in this journey, as I accepted an Assistant Professor position at @UChicago, where I am thrilled to start my own research group in January 2025! (1/5)

[MSK Department of Medicine @MSK_DeptOfMed]

Congrats to Eytan Stein, MD, and team on the publication of their study in @Nature demonstrating that the menin inhibitor revumenib led to deep and sustained remission in children and adults with KMT2A-rearranged or NPM1-mutant leukemia. #leusm #Cancer
https://t.co/jRs5Z5WFM6

[Scott Millman, MD PhD @ScottMillmanMD]

@Lingbo_Zhang @CSHL @BloodJournal Thanks @Lingbo_Zhang! I enjoyed collaborating with your team and hope this will be a useful resource for the leukemia/metabolism community.

[Lingbo Zhang @Lingbo_Zhang]

Thrilled to share new review of Zhang Lab @CSHL "Metabolism in acute myeloid leukemia: mechanistic insights & therapeutic targets" published @BloodJournal! Targeting metabolic dependency including selective vitamin & micronutrient pathway treats leukemia.
https://t.co/ho6GIBAjTn

[Scott Millman, MD PhD @ScottMillmanMD]

@LoweLabMSKCC @NIH Excited to continue my work on AML and metabolism in @LoweLabMSKCC at @MSKCancerCenter. Thank you to all who have supported me in this effort!

[Scott Millman, MD PhD @ScottMillmanMD]

Powerful genetic engineering strategy to study cancer from @MSKCancerCenter named for @officialDannyT's MACHETE.

[Pancho Barriga @barrigafm]

During my postdoc I embarked on understanding this biology and developed MACHETE, a deletion engineering strategy! We uncover that loss of 9p21.3 affects immune surveillance by disrupting both CDKN2A/B and a cluster of linked type I interferons.

[Lowe Lab @LoweLabMSKCC]

New Preprint! Led by #DynamicDuo @BarrigaFM & @KTsanov, this study set out to understand how somatic copy number alterations (CNAs) promote cancer. CNAs are prevalent across cancer types & correlate w/ clinical outcomes but remain difficult to study. 1/n
https://t.co/gKauUVzL0x